Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in two virtual investor conferences in February 2022. The Guggenheim Oncology Conference is scheduled for
Repare Therapeutics (RPTX) provided a corporate update, highlighting significant advancements in 2021 and expectations for 2022. The company reported positive Phase 1 data for RP-3500 and initiated patient enrollment for combination trials. Key milestones include the upcoming Phase 2 TRESR trial for RP-3500, data releases for RP-3500 and RP-6306, and IND-enabling studies for a Polθ inhibitor. Repare ended Q3 2021 with approximately $268.2 million in cash, facilitating operations through 2023. The company will present at the J.P. Morgan Healthcare Conference on January 12, 2022.
Repare Therapeutics has appointed Philip Herman as its EVP Commercial & New Product Development, bringing over 20 years of experience in the pharmaceutical and biotech industries. The company is focused on advancing its lead products,
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that
Repare Therapeutics (NASDAQ: RPTX) has commenced its Phase 1 clinical trial for RP-6306, a pioneering small molecule targeting PKMYT1, combined with gemcitabine for treating advanced solid tumors. The trial, named MAGNETIC, aims to dose approximately 104 patients selected based on genomic alterations. The primary goals include determining the maximum tolerated dose and evaluating preliminary anti-tumor activity. This milestone follows ongoing developments in Repare's precision oncology pipeline, which features several innovative therapeutic candidates.
Repare Therapeutics Inc. (NASDAQ: RPTX) has announced the modification and establishment of Automatic Securities Disposition Plans (ASDPs) by its executives and other insiders. Up to 328,681 shares may be sold under these ASDPs, which are designed to ensure orderly share disposition while adhering to U.S. and Canadian securities regulations. Sales will commence following the announcement of the fiscal year's annual financial statements, with set parameters to prevent trading based on undisclosed information. Repare specializes in precision oncology, focusing on novel cancer treatments.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced participation in two virtual investor conferences in November 2021. The Northland Synthetic Lethality Investor Conference will take place on
Repare Therapeutics (RPTX) presented initial data from its Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference, indicating RP-3500's promising safety and early efficacy in patients with specific genomic alterations. The company raised $101.2 million in a recent follow-on public offering, enhancing its financial position. The Q3 report showed a net loss of $30.9 million, up from $13.8 million year-over-year. R&D expenses increased to $25.4 million due to heightened development activities. Thomas Civik was appointed as the new Chairman of the Board.
Repare Therapeutics Inc. (RPTX) announced the closing of its upsized public offering on November 1, 2021, raising approximately $101.2 million through the sale of 4,600,000 common shares at $22.00 each. The offering included the full exercise of the underwriters' option for an additional 600,000 shares. Major underwriters included Morgan Stanley and Goldman Sachs. This financing positions Repare to further advance its precision oncology initiatives, particularly its clinical candidates, RP-3500 and RP-6306, utilizing its proprietary SNIPRx® platform.
Repare Therapeutics Inc. (RPTX) announced the pricing of a public offering of 4,000,000 common shares at $22.00 each, aiming for total proceeds of $88 million before expenses. The offering is expected to close on November 1, 2021, pending customary conditions. An additional 600,000 shares may be purchased by underwriters within 30 days. This offering is made under a previously filed SEC registration statement. Repare, a precision oncology company, is developing therapies focusing on genomic instability, with notable candidates in various clinical trial phases.
